共 50 条
- [11] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2019, 20 (06): : 806 - 815Jiang, ZefeiLi, WeiHu, XichunZhang, QingyuanSun, TaoCui, ShudeWang, ShusenOuyang, QuchangYin, YongmeiGeng, CuizhiTong, ZhongshengCheng, YingPan, YueyinSun, YupingWang, HongOuyang, TaoGu, KangshengFeng, JifengWang, XiaojiaWang, ShubinLiu, TianshuGao, JinghuaCristofanilli, MassimoNing, ZhiqiangLu, Xianping
- [12] Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialLANCET ONCOLOGY, 2024, 25 (09): : 1231 - 1244Oliveira, MafaldaRugo, Hope S.Howell, Sacha J.Dalenc, FlorenceCortes, JavierGomez, Henry L.Hu, XichunToi, MasakazuJhaveri, KomalKrivorotko, PetrLoibl, SibylleMurillo, Serafin MoralesOkera, MeenaNowecki, ZbigniewPark, Yeon HeeSohn, Joo HyukTokunaga, ErikoYousef, SamihZhukova, LyudmilaFulford, MartaAndrews, HayleeWadsworth, IanD'Cruz, CelinaTurner, Nicholas C.
- [13] TNeoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialLANCET ONCOLOGY, 2019, 20 (09): : 1226 - 1238Saura, CristinaHlauschek, DominikOliveira, MafaldaZardavas, DimitriosJallitsch-Halper, Anitade la Pena, LorenaNuciforo, PaoloBallestrero, AlbertoDubsky, PeterLombard, Janine M.Vuylsteke, PeterCastaneda, Carlos A.Colleoni, MarcoBorges, Giuliano SantosCiruelos, EvaFornier, MonicaBoer, KatalinBardia, AdityaWilson, Timothy R.Stout, Thomas J.Hsu, Jerry Y.Shi, YiPiccart, MartineGnant, MichaelBaselga, Josede Azambuja, Evandro
- [14] Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trialANNALS OF ONCOLOGY, 2020, 31 : S1151 - S1151Jones, R.Casbard, A.Carucci, M.Smith, J.Ingarfield, K.Gee, J. M. W.Hudson, Z.Alchami, F.Hayward, L.Hickish, T.Hwang, D.McAdam, K.Spensley, S.Waters, S.Wheatley, D.Beresford, M.
- [15] Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trialTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15Tibau, AriadnaMartinez, M. TeresaRamos, Manuelde la Cruz-Merino, LuisSantaballa, AnaO'Connor, MiriamMartinez-Janez, NoeliaMoreno, FernandoFernandez, IsauraVirizuela, Juan AntonioAlarcon, Jesusde la Haba-Rodriguez, JuanSanchez-Rovira, PedroAlbacar, Cinta RosaMuino, Coralia BuenoKelly, CatherineCasas, MaribelBezares, SusanaRosell, LibertadAlbanell, Joan
- [16] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016)LANCET ONCOLOGY, 2016, 17 (04): : E136 - E136Cristofanilli, M.Turner, N. C.Bondarenko, I
- [17] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 431, 2016)LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270Cristofanilli, M.Turner, N. C.Bondarenko, I
- [18] Vandetanib Plus Fulvestrant Versus Placebo Plus Fulvestrant After Relapse or Progression on an Aromatase Inhibitor in Metastatic ER-Positive Breast Cancer (FURVA): A Randomised, Double-Blind, Placebo-Controlled, Phase II TrialCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 18 - 19不详
- [19] Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2023, 24 (06): : 646 - 657Zhang, PinZhang, QingyuanTong, ZhongshengSun, TaoLi, WeiOuyang, QuchangHu, XichunCheng, YingYan, MinPan, YueyinTeng, YueeYan, XiWang, YingXie, WeiminZeng, XiaohuaWang, XiaojiaHu, ChangluGeng, CuizhiZhang, HongweiLi, WenxinWu, XinhongZhong, JincaiXu, JingweiShi, YanxiaWei, WenhuaBayaxi, NayimaZhu, XiaoyuXu, Binghe
- [20] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerCLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338Lim, BoraPotter, David A.Salkeni, Mohamad A.Silverman, PaulaHaddad, Tufia C.Forget, FredericAwada, AhmadCanon, Jean-LucDanso, MichaelLortholary, AlainBourgeois, HuguesTan-Chiu, ElizabethVincent, SylvieBahamon, BrittanyGalinsky, Kevin J.Patel, ChiragNeuwirth, RachelLeonard, E. JaneDiamond, Jennifer R.